Development of new thiazolidine-2,4-dione hybrids as aldose reductase inhibitors endowed with antihyperglycaemic activity: design, synthesis, biological investigations, and in silico insights

References

• Pasala VK, Gudipudi G, Sankeshi V, Basude M, Gundla R, Singh Jadav S, Srinivas B, Goud EY, Nareshkumar D. Design, synthesis and biological evaluation of selective hybrid coumarin-thiazolidinedione aldose reductase-II inhibitors as potential antidiabetics. Bioorg Chem. 2021;114:104970.
   PubMed Web of Science ®Google Scholar
• Imran M, Yar MS, Khan SA. Synthesis and antihyperglycemic activity of 2-(substituted phenyl)-3-{[4-(1-naphthyl)-1, 3-thiazol-2-yl] amino}-4-oxo-1, 3-thiazolidin-5-ylacetic acid derivatives. Acta Pol Pharm. 2009;66(1):51–56.
   PubMed Web of Science ®Google Scholar
• Sever B, Altıntop MD, Demir Y, Türkeş C, Özbaş K, Çiftçi GA, Beydemir Ş, Özdemir A. A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity. Open Chem. 2021;19(1):347–357.
   Web of Science ®Google Scholar
• Singh Grewal A, Bhardwaj S, Pandita D, Lather V, Singh Sekhon B. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16(2):120–162.
   PubMed Web of Science ®Google Scholar
• Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin N Am. 1989;18(1):163–183.
   PubMed Web of Science ®Google Scholar
• O Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust. 2002;176(8):381–386.
   PubMed Web of Science ®Google Scholar
• Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999;13(1):23–30.
   PubMed Web of Science ®Google Scholar
• Bozdağ-Dündar O, Evcimen ND, Ceylan-Ünlüsoy M, Ertan R, Sarıkaya M. Some new thiazolyl thiazolidinedione derivatives as aldose reductase inhibitors. Med Chem Res. 2008;16(1):39–47.
   Web of Science ®Google Scholar
• Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr Med Chem. 2009;16(6):734–752.
   PubMed Web of Science ®Google Scholar
• Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 1997;46(Suppl. 2):S82–S89.
   PubMedGoogle Scholar
• Kador PF, Robison WG Jr, Kinoshita JH. The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol. 1985;25:691–714.
   PubMed Web of Science ®Google Scholar
• Costantino L, Rastelli G, Gamberini MC, Barlocco D. Pharmacological approaches to the treatment of diabetic complications. Expert Opin Ther Pat. 2000;10(8):1245–1262.
   Web of Science ®Google Scholar
• Costantino L, Ferrari AM, Gamberini MC, Rastelli G. Nitrophenyl derivatives as aldose reductase inhibitors. Bioorg Med Chem. 2002;10(12):3923–3931.
   PubMed Web of Science ®Google Scholar
• Kousaxidis A, Kovacikova L, Nicolaou I, Stefek M, Geronikaki A. Non-acidic bifunctional benzothiazole-based thiazolidinones with antimicrobial and aldose reductase inhibitory activity as a promising therapeutic strategy for sepsis. Med Chem Res. 2021;30(10):1837–1848.
   PubMed Web of Science ®Google Scholar
• Kratky M, Sramel P, Bodo P, Prnova MS, Kovacikova L, Majekova M, Vinsova J, Stefek M. Novel rhodanine based inhibitors of aldose reductase of non-acidic nature with p-hydroxybenzylidene functional group. Eur J Med Chem. 2023;246:114922.
   PubMed Web of Science ®Google Scholar
• Bacha MM, Nadeem H, Zaib S, Sarwar S, Imran A, Rahman SU, Ali HS, Arif M, Iqbal J. Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies. BMC Chem. 2021;15(1):1–15.
   PubMed Web of Science ®Google Scholar
• Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y, Diabetic Neuropathy Study Group in Japan. Clinical investigation of Epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. J Diabetes Complications. 1996;10(3):168–172.
   PubMed Web of Science ®Google Scholar
• Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, et al. Long-term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care. 2006;29(7):1538–1544.
   PubMed Web of Science ®Google Scholar
• Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther. 1984;229(1):226–230.
   PubMed Web of Science ®Google Scholar
• Das-Evcimen N, Sarıkaya M, Selen Gurkan-Alp A, Bozdag-Dundar O. Aldose reductase inhibitory potential of several thiazolyl-thiazolidine-2,4-diones. Lett Drug Des Discov. 2013;10(5):415–419.
   Web of Science ®Google Scholar
• Bozdağ-Dündar O, Evranos B, Daş-Evcimen N, Sarıkaya M, Ertan R. Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones. Eur J Med Chem. 2008;43(11):2412–2417.
   PubMed Web of Science ®Google Scholar
• Maccari R, Del Corso A, Giglio M, Moschini R, Mura U, Ottanà R. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors. Bioorg Med Chem Lett. 2011;21(1):200–203.
   PubMed Web of Science ®Google Scholar
• Ottanà R, Maccari R, Giglio M, Del Corso A, Cappiello M, Mura U, Cosconati S, Marinelli L, Novellino E, Sartini S, et al. Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. Eur J Med Chem. 2011;46(7):2797–2806.
   PubMed Web of Science ®Google Scholar
• Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (Zopolrestat) and congeners. J Med Chem. 1991;34(1):108–122.
   PubMed Web of Science ®Google Scholar
• Imran A, Shehzad MT, Shah SJA, Al Adhami T, Laws M, Rahman KM, Alharthy RD, Khan IA, Shafiq Z, Iqbal J. Development and exploration of novel substituted thiosemicarbazones as inhibitors of aldose reductase via in vitro analysis and computational study. Sci Rep. 2022;12(1):5734.
   PubMed Web of Science ®Google Scholar
• Aotsuka T, Abe N, Fukushima K, Ashizawa N, Yoshida M. Benzothiazol-2-ylcarboxylic acids with diverse spacers: a novel class of potent, orally active aldose reductase inhibitors. Bioorg Med Chem Lett. 1997;7(13):1677–1682.
   Web of Science ®Google Scholar
• Kotani T, Nagaki Y, Ishii A, Konishi Y, Yago H, Suehiro S, Okukado N, Okamoto K. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J Med Chem. 1997;40(5):684–694.
   PubMed Web of Science ®Google Scholar
• Kotani T, Ishii A, Nagaki Y, Toyomaki Y, Yago H, Suehiro S, Okukado N, Okamoto K. Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. Chem Pharm Bull. 1997;45(2):297–304.
   PubMed Web of Science ®Google Scholar
• Zaher N, Nicolaou I, Demopoulos VJ. Pyrrolylbenzothiazole derivatives as aldose reductase inhibitors. J Enzyme Inhib Med Chem. 2002;17(2):131–135.
   PubMed Web of Science ®Google Scholar
• Kousaxidis A, Petrou A, Rouvim P, Bodo P, Stefek M, Nicolaou I, Geronikaki A. A molecular hybridization approach for the design of selective aldose reductase (ALR2) inhibitors and exploration of their activities against protein tyrosine phosphatase 1B (PTP1B). J Mol Struct. 2023;1271:134116.
   Web of Science ®Google Scholar
• Hussain S, Parveen S, Qin X, Hao X, Zhang S, Chen X, Zhu C, Ma B. Novel synthesis of nitro-quinoxalinone derivatives as aldose reductase inhibitors. Bioorg Med Chem Lett. 2014;24(9):2086–2089.
   PubMed Web of Science ®Google Scholar
• Ishii A, Kotani T, Nagaki Y, Shibayama Y, Toyomaki Y, Okukado N, Ienaga K, Okamoto K. Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J Med Chem. 1996;39(9):1924–1927.
   PubMed Web of Science ®Google Scholar
• Tilekar K, Upadhyay N, Hess JD, Macias LH, Mrowka P, Aguilera RJ, Meyer-Almes F-J, Iancu CV, Choe J-y, Ramaa C. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential. Eur J Med Chem. 2020;202:112603.
   PubMed Web of Science ®Google Scholar
• Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicolo F, Ottana R, Vigorita M. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg Med Chem. 2002;10(4):1077–1084.
   PubMed Web of Science ®Google Scholar
• Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-Ene-4-thiazolidinones – an efficient tool in medicinal chemistry. Eur J Med Chem. 2017;140:542–594.
   PubMed Web of Science ®Google Scholar
• Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009;52(1):74–86.
   PubMed Web of Science ®Google Scholar
• Stana A, Tiperciuc B, Duma M, Vlase L, Crişan O, Pîrnău A, Oniga O. Synthesis and antimicrobial activity of some new N‐substituted‐5‐arylidene‐thiazolidine‐2,4‐diones. J Heterocycl Chem. 2014;51(2):411–417.
   Web of Science ®Google Scholar
• Hurren KM, Dunham MW. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opin Pharmacother. 2021;22(2):131–133.
   PubMed Web of Science ®Google Scholar
• Othman DIA, Hamdi A, Tawfik SS, Elgazar AA, Mostafa AS. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies. J Enzyme Inhib Med Chem. 2023;38(1):2166037.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Hamdi A, Mohamed AAB, El-Shafey HW, Moustafa M, Elgazar AA, Eldehna WM, Ur Rahman H, Parambi DGT, Elbargisy RM, et al. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study. J Enzyme Inhib Med Chem. 2023;38:2166036.
   PubMed Web of Science ®Google Scholar
• El-Senduny FF, Elgazar A, Alwasify HA, Abed A, Foda M, Abouzeid S, Lewerenz L, Selmar D, Badria F. Bio-evaluation of untapped alkaloids from Vinca minor enriched by methyl jasmonate induced stress: an integrated approach. Planta Med. 2023.
   Google Scholar
• Hamdi A, El-Shafey HW, Othman DIA, El-Azab AS, AlSaif NA, Abdel-Aziz AAM. Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: molecular modeling studies. Bioorg Chem. 2022;122:105710.
   PubMed Web of Science ®Google Scholar
• Hamdi A, Elhusseiny WM, Othman DI, Haikal A, Bakheit AH, El-Azab AS, Al-Agamy MH, Alaa A-M. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2,4-dione derivatives: histone deacetylases inhibitory activity and molecular docking study. Eur J Med Chem. 2022;244:114827.
   PubMed Web of Science ®Google Scholar
• Othman DI, Hamdi A, Abdel-Aziz MM, Elfeky SM. Novel 2-arylthiazolidin-4-one-thiazole hybrids with potent activity against Mycobacterium tuberculosis. Bioorg Chem. 2022;124:105809.
   PubMed Web of Science ®Google Scholar
• Islam MS, Al-Majid AM, Azam M, Verma VP, Barakat A, Haukka M, Elgazar AA, Mira A, Badria FA. Construction of spirooxindole analogues engrafted with indole and pyrazole scaffolds as acetylcholinesterase inhibitors. ACS Omega. 2021;6(47):31539–31556.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Hamdi A, Brogi S, Tawfik SS, Othman DIA, Elshal M, Ur Rahman H, Parambi DGT, Elbargisy RM, Selim S, et al. Design, synthesis, and biological investigation of oxadiazolyl, thiadiazolyl, and pyrimidinyl linked antipyrine derivatives as potential non-acidic anti-inflammatory agents. J Enzyme Inhib Med Chem. 2023;38(1):2162511.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Chilingaryan G, Abelyan N, Mamikonyan M, Gasparyan H, Hovhannisyan S, Hamdi A, Ali AR, Selim S, Mohamed AA. Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors. PLOS One. 2022;17(9):e0272065.
   PubMed Web of Science ®Google Scholar
• Martinez A, Alonso M, Castro A, Dorronsoro I, Gelpí JL, Luque FJ, Pérez C, Moreno FJ. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem. 2005;48(23):7103–7112.
   PubMed Web of Science ®Google Scholar
• Kumar H, Aggarwal N, Marwaha MG, Deep A, Chopra H, Matin MM, Roy A, Emran TB, Mohanta YK, Ahmed R, et al. Thiazolidin-2,4-dione scaffold: an insight into recent advances as antimicrobial, antioxidant, and hypoglycemic agents. Molecules. 2022;27(19):6763.
   PubMed Web of Science ®Google Scholar
• Long N, Le Gresley A, Wren SP. Thiazolidinediones: an in-depth study of their synthesis and application to medicinal chemistry in the treatment of diabetes mellitus. ChemMedChem. 2021;16(11):1717–1736.
   Web of Science ®Google Scholar
• Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A. Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus. Eur J Med Chem. 2020;207:112742.
   PubMed Web of Science ®Google Scholar
• Lee YS, Chen Z, Kador PF. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg Med Chem. 1998;6(10):1811–1819.
   PubMed Web of Science ®Google Scholar
• Wilson DK, Tarle I, Petrash JM, Quiocho FA. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor Zopolrestat. Proc Natl Acad Sci USA. 1993;90(21):9847–9851.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options. J Pharm Sci. 2017;106(4):921–929.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
   Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–2623.
   PubMed Web of Science ®Google Scholar
• El-Shafey HW, Gomaa RM, El-Messery SM, Goda FE. Quinazoline based HSP90 inhibitors: synthesis, modeling study and ADME calculations towards breast cancer targeting. Bioorg Med Chem Lett. 2020;30(15):127281.
   PubMed Web of Science ®Google Scholar
• Wang R, Fu Y, Lai L. A new atom-additive method for calculating partition coefficients. J Chem Inf Comput Sci. 1997;37(3):615–621.
   Google Scholar
• Peprah K, Zhu XY, Eyunni SVK, Etukala JR, Setola V, Roth BL, Ablordeppey SY. Structure–activity relationship studies of SYA 013, a homopiperazine analog of haloperidol. Bioorg Med Chem. 2012;20(5):1671–1678.
   PubMed Web of Science ®Google Scholar
• Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, Lai L, Pei J, Li H. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356–W360.
   PubMed Web of Science ®Google Scholar
• Nnyigide OS, Nnyigide TO, Lee S-G, Hyun K. Modeling, protein repair and analysis server: a web server to repair PDB structures, add missing heavy atoms and hydrogen atoms, and assign secondary structures by amide interactions. J Chem Inf Model. 2022;62(17):4232–4246.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–2786.
   Google Scholar
• Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243–250.
   PubMedGoogle Scholar
• Elimam DM, Elgazar AA, El-Senduny FF, El-Domany RA, Badria FA, Eldehna WM. Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer. J Enzyme Inhib Med Chem. 2022;37(1):39–50.
   PubMed Web of Science ®Google Scholar